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 Introduction 
 Heparan sulfate proteoglycans (HSPGs) comprise a complex 
and heterogeneous family of macromolecules that are prefer-
entially located at the cell surface and basement membrane 
( Whitelock and Iozzo, 2005; Knox and Whitelock, 2006 ;  Bishop 
et al., 2007 ). Perlecan, an archetypal HSPG with a large multi-
valent protein core, regulates basement membrane assembly, 
vascular and cartilage development, and tumor growth and 
angiogenesis ( Mathiak et al., 1997 ;  Iozzo, 1998 ;  Iozzo and San 
Antonio, 2001 ;  Hassell et al., 2002 ). The biology of perlecan 
extends far beyond the original notion as an anionic fi lter. This 
complex molecule has a  variety of roles: perlecan is a structural 
constituent of basement membranes and is a key regulator of 
several growth factor signaling pathways and lipid metabolism 
( Fuki et al., 2000 ;  Iozzo, 2005 ;  Lindner et al., 2007 ). Moreover, 
although as a parent molecule, perlecan is proangiogenic ( Aviezer 
et al., 1994 ;  Sharma et al., 1998 ;  Iozzo and San Antonio, 2001 ), 
a C-terminal perlecan fragment named endorepellin has anti-
angiogenic activity in tumor xenograft models ( Mongiat et al., 
2003 ;  Bix et al., 2004, 2006 ;  Woodall et al., 2008 ). Proteomic 
profi ling of endorepellin-targeted action on the endothelium has 
recently identifi ed fi ve key proteins involved with endorepellin 
angiostatic activity ( Zoeller and Iozzo, 2008 ). 
 The multiple developmental roles of perlecan are diffi cult 
to dissect in placental animals because disruption of the per-
lecan gene leads to embryonic lethality ( Arikawa-Hirasawa 
et al., 1999 ;  Costell et al., 1999 ). Nearly half of the perlecan-null 
mice die at embryonic days 10 – 12 because of hemorrhage 
within the pericardial cavity ( Costell et al., 1999 ). The animals 
that survive exhibit severe cephalic and cartilage abnormalities 
and die of respiratory failure just after birth ( Arikawa-Hirasawa 
et al., 1999 ). The phenotype of perlecan-null animals is quite 
complex in so far as a close analysis of all of the embryos that 
reach later stages of development show malformations of the 
cardiac outfl ow tract, including transposition of the great vessels 
and abnormal coronary artery development ( Costell et al., 2002 ; 
 Gonz á lez-Iriarte et al., 2003 ). A viable mutant animal has been 
generated in which mice lack perlecan exon 3, which contains 
two of the three possible heparan sulfate attachment sites ( Rossi 
et al., 2003 ). Interestingly, the animals are viable and fertile but 
have small eyes and show degeneration of the lens within 3 wk 
of birth ( Rossi et al., 2003 ). Various experimental challenges of 
 Perlecan ’ s developmental functions are difﬁ cult to dis-sect in placental animals because perlecan disruption is embryonic lethal. In contrast to mammals, cardio-
vascular function is not essential for early zebraﬁ sh develop-
ment because the embryos obtain adequate oxygen by 
diffusion. In this study, we use targeted protein depletion 
coupled with protein-based rescue experiments to investigate 
the involvement of perlecan and its C-terminal domain V/
endorepellin in zebraﬁ sh development. The  perlecan mor-
phants show a severe myopathy characterized by abnormal 
actin ﬁ lament orientation and disorganized sarcomeres, 
suggesting an involvement of perlecan in myopathies. 
In the  perlecan morphants, primary intersegmental vessel 
sprouts, which develop through angiogenesis, fail to ex-
tend and show reduced protrusive activity. Live video-
microscopy conﬁ rms the abnormal swimming pattern caused 
by the myopathy and anomalous head and trunk vessel 
circulation. The phenotype is partially rescued by micro-
injection of human perlecan or endorepellin. These ﬁ nd-
ings indicate that perlecan is essential for the integrity of 
somitic muscle and developmental angiogenesis and that 
endorepellin mediates most of these biological activities.
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 Results 
 Cloning and developmental expression of 
zebraﬁ sh  perlecan 
 We characterized the zebrafi sh  perlecan sequence by elec-
tronic PCR and cloned zebrafi sh  endorepellin by RT-PCR (TPA 
BK006379). From a comprehensive database analysis, we conclude 
that zebrafi sh perlecan has an overall structure similar to the mam-
malian counterpart with an estimated  M r of   370 kD ( Fig. 1 A ) and 
good conservation of domains II – V (Tables S1 and S2, available at 
http://www.jcb.org/cgi/content/full/jcb.200708022/DC1). Notably, 
zebrafi sh  perlecan lacked the fi rst 56 amino acid residues and 
did not contain the SGD triplets present in the mammalian counter-
part where the heparan sulfate chains are attached. However, 
there are 14 SG dipeptides dispersed throughout domains III – V 
(Table S2), with several of those conforming to the glycosamino-
glycan-binding consensus found in other HSPGs ( Bishop et al., 
2007 ;  Wang et al., 2007 ). Initial experiments showed that ze bra-
fi sh  perlecan is indeed an HSPG because it was completely 
 resistant to chondroitinase ABC but was sensitive to heparitinase 
treatment (unpublished data). The exact domain in which the hep-
aran sulfate chains are attached is not yet known. Moreover, nine 
Ig repeats were not present in zebrafi sh perlecan. Analysis of the 
available zebrafi sh database showed that there is one single gene 
encoding zebrafi sh  perlecan and that it was localized to chromo-
some 23 syntenic to human chromosome 1 and mouse chromo-
some 4, where the mammalian orthologues are located ( Fig. 1 B ). 
Comparative analysis of human, mouse, zebrafish, and  Dro-
sophila melanogaster domain V/endorepellin showed a high de-
gree of conservation with   60% sequence identity and  > 70% 
homology between human and zebrafi sh endorepellin (Fig. S1 A). 
these heparan sulfate – defi cient mice result in increased stenosis 
in injured carotid arteries ( Tran et al., 2004 ) and impaired angio-
genesis and tumor growth ( Zhou et al., 2004 ). 
 In contrast to mammals, intact cardiovascular function is 
not essential for early zebrafi sh development because the em-
bryos obtain adequate oxygen by simple diffusion from the en-
vironment. Morpholino-modifi ed antisense knockdown of the 
 perlecan gene allows the morphant embryos to survive for days 
essentially half-way through early larval development (  7 d 
postfertilization [dpf]), thereby permitting, for the fi rst time, a 
detailed analysis of the role of perlecan in various systems dur-
ing early and late embryogenesis. 
 In this study, we focused on the role of perlecan in zebrafi sh 
muscle and cardiovascular development. The  perlecan mor-
phants showed a severe myopathy characterized by abnormal 
fiber orientation, reduced amounts of actin filaments, and 
 disorganized sarcomeres, suggesting a potential role for per-
lecan in human myopathies. Moreover, primary intersegmental 
vessel (ISV) sprouts initiated but did not completely extend and 
showed reduced protrusive activity; often the sprouts were very 
thin and blunt ended and either failed to anastomose or formed 
irregular junctions. Live videomicroscopy confi rmed both the 
abnormal swimming motion caused by the muscular defects 
and the anomalous circulation in the head and trunk vessels. 
The morphant phenotype could be partially rescued by micro-
injection of human perlecan isolated from endothelial cells or 
by its C-terminal domain V/endorepellin. Collectively, our fi nd-
ings indicate that perlecan is essential for the development and 
integrity of somitic muscle and developmental angiogenesis 
and that its C-terminal module endorepellin mediates most of 
these biological activities. 
 Figure 1.  Analysis of zebraﬁ sh  perlecan . (A) Schematic of human and zebraﬁ sh  perlecan protein core. The roman numerals indicate the ﬁ ve domains. 
A key for the various modules is presented at the bottom. Arrows indicate the perlecan MO-DI, MO-DIII, and MO-DV morpholino targeting sites. See Fig. S1 
for additional information (available at http://www.jcb.org/cgi/content/full/jcb.200708022/DC1). (B) Zebraﬁ sh perlecan is conserved syntenically. 
The zebraﬁ sh  perlecan gene ( hspg2 ) maintains a syntenic relationship with DDOST, PHC2, and SARS of mammalian species. Species and respective 
chromosome number are depicted; gene symbols are followed by the gene identiﬁ cation numbers from the National Center for Biotechnology Information 
Entrez Gene database, and distances between genes are displayed in megabases. 
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1997 ) showed strong positivity at the 64- and 1,000-cell stage 
2 and 3 h postfertilization (hpf;  Fig. 2, I and J ), at a time when 
zygotic transcription has not yet commenced, indicating that 
 perlecan was maternally derived. At 1 – 2 dpf, perlecan epitopes 
were detected in the head region, in the developing eyes, along 
the myoseptae, and at the major axial vessels ( Fig. 2, L – N ), 
which is in agreement with the ISH results. The robust early 
embryonic expression of zebrafi sh  perlecan indicates that this 
gene product is important for early embryogenesis. 
 Perlecan is essential for zebraﬁ sh 
embryonic development 
 To asses the developmental roles of perlecan, we selectively 
blocked the translation of  perlecan mRNA using morpholino anti-
sense oligonucleotides (MO), a specifi c translation inhibitor in 
zebrafi sh ( Nasevicius and Ekker, 2000 ). We initially used two 
morpholinos of nonoverlapping sequence: one directed against 
the translation start site (MO-DI) of  perlecan and the other en-
compassing the splice donor site of the initial exon of domain V/
endorepellin (MO-DV;  Fig. 1 A ). Embryos at the one- to two-
cell stage were injected with 2.5 – 10 ng morpholino, and embryos 
The BMP-1 – sensitive site that would liberate the last globular 
 domain of endorepellin, LG3, was perfectly conserved among 
 human, mouse, and zebrafi sh, further stressing the potential bio-
logical signifi cance of this protease-sensitive site ( Gonzalez et al., 
2005 ). Phylogenetic analysis of endorepellin from 13 separate 
species (Fig. S1 B) indicates that zebrafi sh and mammalian 
endorepellin evolved from a common ancestor. 
 To determine the spatiotemporal expression of zebrafi sh 
 perlecan , we used whole mount in situ hybridization (ISH) and 
immunohistochemistry. ISH using a domain V antisense RNA 
probe showed the prominent expression of  perlecan at the 20-
 somite stage in the head and somite region ( Fig. 2, A and B ). 
 Perlecan was more clearly expressed at 1 dpf in these regions and 
was localized along the lateral myotomes ( Fig. 2 C ) and in the 
major axial vessels ( Fig. 2 D ). At 5 dpf,  perlecan was expressed 
in the head and intestinal organs, with strong positivity in the 
 axial vessels, including the dorsal aorta (DA) and the dorsal lon-
gitudinal anastomotic vessel (DLAV) as well as in the myoseptae, 
the ISVs, and posterior cardinal vein (PCV;  Fig. 2, F and G ). 
 Whole mount immunohistochemistry using an affi nity-
purifi ed rabbit anti – mouse perlecan antibody ( Handler et al., 
 Figure 2.  Spatiotemporal expression patterns of zebraﬁ sh  perlecan mRNA and protein. (A – G) Whole mount ISH with a digoxigenin-labeled perlecan 
domain V antisense probe for the localization of  perlecan mRNA (blue/purple staining).  Perlecan mRNA can be detected at the 20-somite stage in regions 
of the developing brain (A) and along both sides of the notochord (B, arrows). At 1 dpf,  perlecan expression is seen in the head region (C), in the devel-
oping somites (C, black arrows), and within the developing axial vasculature (D, arrows). Also note perlecan expression localized within the duct of 
Cuvier (C, red arrows). By 5 dpf (F and G [magniﬁ ed image of the region boxed in F]),  perlecan expression signiﬁ cantly increases throughout the trunk 
musculature (G, arrows), the major trunk/tail vessels including the DLAV, DA, and PCV, and in the developing gastrointestinal tract and future ﬁ n regions. 
(E) ISH with a digoxigenin-labeled perlecan domain V sense probe. ISH was performed in groups of two to ﬁ ve samples, and representative images are shown. 
(H – N) Whole mount immunohistochemistry with an afﬁ nity-puriﬁ ed anti – mouse perlecan antibody. Perlecan can be detected as early as the 64- and 
1,000-cell stage of embryonic development (2 and 3 hpf, respectively) throughout the cell mound (I and J). At 1 dpf, perlecan protein (L and M) is detected 
throughout the head (L, arrow), trunk, and tail and is speciﬁ cally localized to the developing muscle myoseptae (M, arrows) and the developing vasculature. 
By 2 dpf (N), perlecan protein is speciﬁ cally detected in the trunk vasculature, including the DLAV (N, black arrows) and axial vessels (N, white arrows). 
(H and K) Immunohistochemistry images in which the primary antibody was omitted. Bars, 500  μ m. 
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 cardiovascular and musculoskeletal systems that became visible at 
1 dpf (Fig. S2 A, available at http://www.jcb.org/cgi/content/full/
jcb.200708022/DC1) and became progressively more apparent as 
development proceeded (Fig. S2, B – E). At 2 dpf, the morphants 
displayed a pronounced curvature of the tail and trunk, which 
could be classifi ed as mild, moderate, or severe twisting of the 
from the same matings were injected with an equal volume of phe-
nol red/nuclease-free water mixture as a control. Higher morpho-
lino concentrations (5 – 10 ng) caused signifi cant lethality, especially 
for MO-DV; thus, we used 2.5 ng or less of the morpholinos. Both 
morpholinos produced an identical phenotype  > 90% ( n = 358; 
P  < 0.001; 10 independent experiments) with severe defects in the 
 Figure 3.  Classiﬁ cation and veriﬁ cation of the  perlecan morphant phenotype. (A) All observed  perlecan morphant phenotypes can be classiﬁ ed according 
to the degree of body twisting as presented for MO-DI. Categories include mild (least striking twisted body but noted tail phenotype), moderate (general 
twisted body usually accompanied by curly tail up), and severe (signiﬁ cant body plan shortening accompanied by twisting of the tail). (B) Mean observed 
frequencies of the twisted body classes from MO-DI  perlecan morphant embryos ( n = 232). Error bars represent  ± SEM. (C) Phenotypic overview of perlecan 
splice junction – blocking MO-DIII. (D) RT-PCR veriﬁ cation of domain III splice junction – blocking morpholino effect. Note the band shift in morpholino-injected 
embryos (lane 5) versus uninjected embryos (lane 4), verifying the splice-blocking/intron retaining effect of MO-DIII. Lane 1, DNA ladder; lane 2, domain III 
PCR from zebraﬁ sh cDNA template; lane 3, domain III PCR from genomic DNA template; lane 4, domain III PCR from uninjected embryos ’ cDNA template; 
lane 5, domain III PCR from MO-DIII – injected embryos ’ cDNA template. The bottom bands in lanes 4 and 5 represent the   -actin control. Template from lanes 
4 and 5 were derived from total RNA isolated from 23 embryos. See  Fig. 1 A for additional details regarding the targeting positions of the morpholinos. 
(E – G) Whole mount immunohistochemistry for veriﬁ cation of domain III morpholino-based knockdown of  perlecan . (E) Control uninjected embryo (2 dpf) shows 
perlecan expression throughout the trunk musculature and vasculature. (F and G) MO-DIII embryos (2 dpf) show signiﬁ cantly reduced perlecan protein levels 
in the trunk, with only minimal staining detected in the head and tail. A and E – G are left-side views with dorsal up and anterior to the left. Bars, 500  μ m. 
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 Figure 4.  Ultrastructural analysis of  perlecan morphant embryos. (A and B) Parasagittal epon sections stained with toluidine blue from 4 dpf control (A) and 
MO-DV morphant embryos (B). Note the irregular structure and organization of the morphant ’ s skeletal muscle and associated abnormal u-shaped myoseptal 
boundaries. The DA appears collapsed in the morphant and devoid of blood cells. NC, notochord; DA, dorsal aorta; PCV, posterior cardinal vein. (C – I) A comparison 
of morphant and control basement membrane structure. Electron microscopy of the vascular (C – E), epithelial (F and G), and notochord basement membranes (BM; 
H and I) suggest that morpholino-based perlecan knockdown does not compromise the integrity of the basement membrane. Bars: (A and B) 25  μ m; (C – I) 1  μ m. 
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 Figure 5.  Perlecan morphants display a complex muscular dystrophy phenotype. (A, D, and F) Ultrastructural analysis of control skeletal muscle from a 5-dpf 
embryo. Parasagittal (A) and cross sections (D and F) of trunk muscle show typical muscular architecture with alignment of z bands, abundant glycogen (Gly) 
and mitochondria (Mi), and typical hexagonal arrays of thick and thin ﬁ laments (D). High magniﬁ cation view shows thick ﬁ laments surrounded by six thin 
ﬁ laments (circle in F). In contrast,  perlecan morphants induced by either translation-blocking (B) or splice-blocking (C, E, and G) morpholinos show disarray of 
muscular architecture with loss of ﬁ laments and irregular ﬁ laments traversing the sarcomeres at variable angles (arrows in B and C). Also notice the presence 
of areas with reduced thin ﬁ laments (asterisks in E) adjacent to more normal-appearing hexagonal structures (E). The sarcoplasmic reticulum (SR) appears to 
be normal (E). High magniﬁ cation of the area labeled by the asterisk in E shows abnormal arrangement of thin and thick ﬁ laments (circle in G). Bars, 1  μ m. 
body ( Fig. 3, A and B ). The morphants exhibited either no escape 
response or uncoordinated movements in response to tactile stim-
uli and often swam in a circular fashion (Video 1). 
 To further corroborate the specifi city of the morpholino-
induced  perlecan phenotype, we used an additional splicing-
blocking morpholino-targeting domain III (MO-DIII;  Fig. 1 A ). 
The phenotype evoked by MO-DIII was identical to that evoked 
by MO-DI and MO-DV ( Fig. 3 C ). In fi ve independent experi-
ments ( n = 192), MO-DIII injections caused a phenotype in 93  ± 
5% of the injected embryos (P  < 0.001). To establish that  perlecan 
knockdown was responsible for the developmental anomalies, 
we purifi ed total RNA from pooled control and MO-DIII – treated 
embryos ( n = 23 for each group) and performed RT-PCR using 
two primers fl anking the targeted exon of domain III. The pre-
dicted unprocessed RNA induced by MO-DIII would yield a 
band of   300 bp, whereas the processed RNA would yield a 
band of   150 bp. As positive controls, we used cDNA ( Fig. 3 D , 
lane 2) and genomic DNA ( Fig. 3 D , lane 3). MO-DIII com-
pletely abolished the properly processed  perlecan mRNA as 
shown by the exclusive presence of the longer transcript of 300 bp 
( Fig. 3 D , lane 5) in contrast to the untreated embryos, which 
showed only the processed RNA band of 150 bp ( Fig. 3 D , lane 4). 
In support of the specifi c perlecan knockdown, whole mount 
immunohistochemistry with the antiperlecan antibody showed a 
marked suppression of perlecan expression in the morphants 
( Fig. 3, F and G ) as compared with controls ( Fig. 3 E ). The ef-
fects of the three morpholinos phenocopied each other, providing 
evidence that the observed developmental defects were specifi c 
for perlecan knockdown. The observed  perlecan morphant ’ s 
phenotype does not appear to be the result of developmental de-
lay because we observed the onset of the heart beat and pigment 
development in all embryos. The morphants also exhibited a pro-
gressive dilatation of the pericardial sac in  > 90% of the cases. 
The embryos with the most severe phenotype survived 2 – 3 d, 
whereas the milder phenotype survived up to 7 – 9 dpf, at which 
time all of the morphants expired with severe generalized edema 
and cardiac failure, as shown by a progressive reduction in ven-
tricular function and contractility. 
 To further prove the specifi city of the observed  perlecan 
knockdown phenotype, we performed two additional experiments 
in which we injected MO-DI and a morpholino targeting the p53 
gene. The rationale for these studies is based on a recent report that 
morpholinos can nonspecifi cally activate the p53 gene, causing 
off-target phenotypic effects that are not caused by the specifi c 
morpholino used ( Robu et al., 2007 ). In both experiments, the 
coinjection of MO-DI and p53 morpholino maintained the MO-DI 
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control and morpholino-treated embryos. The muscular pheno-
type was evident at 2 dpf with signifi cant loss of myofi laments 
and disruption of mitochondria (Fig. S3, available at http://www
.jcb.org/cgi/content/full/jcb.200708022/DC1). However, the mus-
cular phenotype became progressively more severe with time. 
By 5 dpf, control embryos exhibited a well-defi ned muscle struc-
ture, with highly organized bundles of myofi bers surrounded by 
mitochondria and glycogen ( Fig. 5 A ). In contrast, morphants 
induced by either translation- or splice-blocking morpholinos 
showed a marked disarray of muscle fi bers ( Fig. 5, B and C ). 
Often, the fi laments appeared to be interwoven, and clear (less 
electron dense) bands traversed the sarcomeres at a longitudinal 
angle, whereas the I bands, the clear bands containing the thinner 
and darker Z bands, were often misaligned and tortuous ( Fig. 5 C ). 
In cross sections, control fi laments were assembled in a hexago-
nal arrangement typical of mature myofi brils, with each thick 
fi lament (myosin fi laments) encircled by six thin fi laments of 
actin that are situated at the trigonal positions of the lattice so 
that each is shared by three equidistant thick fi laments ( Fig. 5, 
D and F ). In the  perlecan morphants, cross section analysis con-
fi rmed the misalignment and irregular ultrastructure observed in 
the longitudinal sections. Specifi cally, we found irregular hexag-
onal arrays and areas in which the thick fi laments were not asso-
ciated with thin fi laments ( Fig. 5 E ). Because of the interwoven 
and twisted nature of the sarcomere, it was difficult to take 
focused electron micrographs, and, in the few exceptions, the thin 
fi laments of actin were irregularly aligned with the thick myosin 
fi laments ( Fig. 5 G ). Essentially, myofi laments were present but 
incorrectly oriented. However, the structure of the sarcoplasmic 
reticulum was fully preserved. 
 Next, we investigated the distribution of actin-containing 
fi laments using fl uorescently labeled phalloidin. The morphants 
phenotype (Fig. S2 F), further confi rming the specifi city of MO-DI 
phenotypic effects. Any observed defects in head, brain, or eye 
development are likely nonspecifi c side effects of MO-DI morpho-
lino because coknockdown with p53-MO did not maintain these 
phenotypic abnormalities. Additionally, a morpholino standard 
control oligonucleotide did not induce any phenotype (Fig. S2 F). 
 Perlecan is not required for the formation 
of most basement membranes 
 Longitudinal sections of the trunk of 4-dpf control zebrafi sh 
showed a well-formed DA fi lled with red cells and a properly 
developed PCV ( Fig. 4 A ). In contrast, in the  perlecan mor-
phants, the lumen of the DA was often collapsed and devoid of 
erythrocytes at 4 dpf ( Fig. 4 B ), although at earlier time points, 
the lumen was patent with circulation (see Perlecan is essential 
for developmental angiogenesis...). In addition, we observed a 
signifi cant disruption of the muscular architecture in the  per-
lecan morphants, with numerous vacuolizations and nucleated 
cells indicating muscle regeneration ( Fig. 4 B ). These lesions 
were found throughout the entire myotome, suggesting an es-
sential role for perlecan in muscle development and mainte-
nance. Ultrastructural analysis of various basement membranes, 
including vessels, skin, and notochord, showed no signifi cant 
alterations in the morphants ( Fig. 4, C – I ), which is in agreement 
with the perlecan-null mice in which basement membrane 
assembly is developmentally normal ( Arikawa-Hirasawa et al., 
1999 ;  Costell et al., 1999 ). 
 Loss of perlecan causes an unexpected 
severe myopathy 
 To understand the effects of  perlecan knockdown on muscle pat-
terning, we performed a detailed ultrastructural analysis of the 
 Figure 6.  Muscular analysis in  perlecan morphant embryos.  ( A and C) Filamentous actin confocal immunohistochemistry. Arows in C highlight clear 
spaces between the muscle ﬁ bers. (B and D) Corresponding DIC analysis of the trunk musculature from a control and morphant embryo at 5 dpf. (E – J) 
Birefringence analyses under polarizing light comparing control and morphant trunk muscle at 2 – 3 dpf. F, H, and J are magniﬁ ed views of the boxed re-
gions in E, G, and I, respectively. Arrows in H indicate regions of hypobirefringence. (K – N) Binding of ﬂ uorescently labeled   -bungarotoxin and fasciculin 
to 4-dpf control and morphant embryos as a means to examine the distribution of AChR (red; highlighted by arrowheads in K and N) and AChE (green; 
highlighted by arrows in L and M). Bars, 300  μ m. 
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vascular markers of vascular cell fate and specifi cation ( Carmeliet, 
2005 ). Thus, in both transgenic fi sh, there is an endothelial-specifi c 
expression of  gfp , thereby allowing continuous in vivo observa-
tion of vertebrate embryonic vascular development. 
 In contrast to the axial vessels, DA and PCV, the ISVs and 
parachordal vessels develop through angiogenesis ( Childs et al., 
2002 ). The ISVs are the primary sprouts emerging from the DA at 
  1 dpf. They are partially patent by 1.5 dpf and fully functional by 
2 dpf ( Isogai et al., 2003 ). The ISVs follow a pattern that is indepen-
dent from circulation and is tightly regulated by spatially and tem-
porally defi ned genetic cues ( Childs et al., 2002; Isogai et al., 2003 ). 
As the growing ISVs approach the dorsolateral roof of the neural 
tube, they divide into two major branches that turn caudally and 
rostrally to form the DLAVs ( Isogai et al., 2001, 2003 ). The second-
ary angiogenic sprouts emerge exclusively from the PCV and de-
velop into the primary vascular network. The parachordal vessels, 
which are positioned along the horizontal myoseptae at either side 
of the notochord, arise by angiogenic growth of secondary sprouts 
from the PCV ( Isogai et al., 2003 ). The  perlecan morphants showed 
relatively well-developed axial vessels but exhibited signifi cant 
suppression of ISVs as compared with control embryos ( Fig. 7, 
A – D ). At 2 dpf, the ISVs were only partially formed, and the 
DLAVs were not formed at all in the most severe phenotypes in-
duced by the translation-blocking morpholino MO-DI. The sprouts 
exhibited a reduced protrusive activity and were very thin and blunt 
ended. The endothelial cells often did not completely migrate along 
the myoseptae from the DA ( > 90%;  n = 287 in six separate experi-
ments) and followed abnormal paths failing to interconnect. In most 
cases, the ISV stopped at the level of the notochord ( Fig. 7, 
B and D ) and failed to form the regular lattice of vessels present on 
either side of the trunk. At later stages, some ISV sprouts reached 
the DLAV level, but they did not properly assemble these vessels, 
and several misguided vessel branches were noted growing away 
from the vertical myoseptae (Fig. S4, available at http://www.jcb
.org/cgi/content/full/jcb.200708022/DC1). The persistence of these 
anomalous vessels at 3 – 4 dpf indicates that the phenotype of the 
perlecan morphants is not the result of just a nonspecifi c develop-
mental delay caused by the morpholino injection. Identical vascu-
lar changes were generated by the splice-blocking morpholino 
MO-DV ( n = 225; six independent experiments; Fig. S5, A – H). 
 The  perlecan morphants induced in the  vegfr2-gfp trans-
genic zebrafi sh also produced an identical phenotype with a 
poorly formed angiogenic network (Fig. S5, I – N). In addition, 
there was pericardial edema and stretching of the atrium and ven-
tricle, which became more severe with time (Fig. S5, K – N). Similar 
results were obtained with the splicing morpholinos MO-DV 
and MO-DIII (unpublished data). Overall, there was a concurrent 
reduction in heart beats per minute with a mean of 98  ± 8 for the 
morphants versus 158  ± 11 for the controls ( n = 24; P  < 0.001). 
 By live DIC videomicroscopy, we observed robust circu-
lation in the control heart, head, and axial vessels as well as the 
various branches emanating from the DA, PCV, and DLAV 
(Videos 2 and 4, available at http://www.jcb.org/cgi/content/
full/jcb.200708022/DC1). In contrast, in the most severe pheno-
type caused by the knockdown of  perlecan , we observed 
no  circulation in the head and trunk regions in spite of robust 
heart contraction (Video 3). In the milder morphant phenotype, 
exhibited blocky somites, with less defi ned chevron-shaped 
boundaries and often clear spaces between the muscle fi bers 
( Fig. 6 C , arrows). The muscle bundles were often interwoven, 
which is better illustrated under differential interference con-
trast (DIC) microscopy ( Fig. 6 D ), as compared with the regular 
array of muscle bundles in the control larvae ( Fig. 6, A and B ). 
 Examination of control embryos using polarized light 
microscopy, a technique used to investigate various muscle mu-
tant zebrafi sh ( Granato et al., 1996 ;  Kunkel et al., 2006 ), revealed 
that axial muscle was highly birefringent at 2 dpf ( Fig. 6, 
E and F ) as a result of the ordered array of myofi laments in striated 
muscle. In contrast,  perlecan morphants showed an overall de-
crease in birefringence with patchy areas of hypobirefringence, 
suggesting a severe disruption of the sarcomeric structures 
( Fig. 6, G and H ). Moreover, in the morphants with a moderate 
phenotype, the chevron-shaped myoseptae were smooth and 
u shaped ( Fig. 6, I and J ). 
 Next, we studied the muscular expression of acetylcholine 
esterase (AChE) and its receptor (acetylcholine receptor [AChR]) 
in control and morphant embryos. The rationale for these studies 
is based on the fact that a set of molecules, including AChE, 
AChR, perlecan, and dystroglycan, cluster at the neuromuscular 
junction, where muscle contraction is initiated ( Rotundo, 2003 ). 
The collagen-tailed form of AChE is highly expressed in the in-
nervated regions of skeletal muscle fi bers and is attached to the 
synaptic basement membrane. It has been shown that perlecan 
is essential for targeting of the collagen-tailed form of AChE to 
the neuromuscular junction ( Arikawa-Hirasawa et al., 2002 ). 
We used whole mount zebrafi sh embryos at 4 dpf and two toxins, 
AlexaFluor488-labeled fasciculin (green) and AlexaFluor555-
labeled   -bungarotoxin (red), to label AChE and AChR, respec-
tively. In control zebrafi sh trunk, AChR was distributed as a fi ne 
array along the fi bers and at myoseptal junctions ( Fig. 6 K ), 
whereas AChE labeling was diffuse with focal clustering at the 
myoseptal junctions ( Fig. 6 L). The  perlecan morphants dis-
played a marked reduction and mislocalization of AChR, and 
short clusters of AChE were detected at the myoseptal junctions, 
often with skipping of somites ( Fig. 6 M ). In the most severe 
morphants, AChR clustered to intersomitic septae ( Fig. 6 N ), 
with the somites mostly devoid of AChR. 
 Collectively, our fi ndings indicate that perlecan is essen-
tial for the development and integrity of somitic muscle and 
suggest a relationship between AChR and perlecan. The lesions 
were found throughout the entire myotomes, demonstrating an 
essential role for perlecan in skeletal muscle development and 
maintenance. The loss and misalignment of myofi laments could 
potentially induce abnormal and uncoordinated movement. This 
could provide a plausible explanation for twisting of the body 
and tail and for the circular swimming observed in the  perlecan 
morphants with severe phenotypes (Video 1). 
 Perlecan is essential for developmental 
angiogenesis and cardiovascular function 
 To monitor vascular development, we used two transgenic zebra-
fi sh expressing  gfp under the guidance of either the  fl i1 ( Lawson 
and Weinstein, 2002 ) or  vegfr2 promoter ( Cross et al., 2003 ). 
The transcription factor  fl i1 and  vegfr2/fl k1 are two endodermal 
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morphants showed a marked reduction in alkaline phosphatase 
staining of the head and axial vessels and a total absence of SIV 
labeling ( Fig. 7, G – J ). The profound effects of  perlecan knock-
down on endothelial cell alkaline phosphatase activity suggests 
that the vascular changes are not secondary to abnormal somitic 
muscle development but are specifi c for endothelial cells, fur-
ther proving the signifi cant effects of  perlecan defi ciency on 
developmental angiogenesis. We conclude that  perlecan is es-
sential for both robust migration of the primary endothelial 
sprouts and for maintaining the path of these vessels along the 
vertical myoseptae. 
we saw regular blood fl ow through the axial vessels but a greatly 
diminished or absent circulation in the ISVs and DLAVs 
(Videos 5 and 6). These results indicate that the disrupted or 
malformed ISVs and DLAVs are not functionally patent in the 
perlecan morphants. 
 Next, we examined endogenous alkaline phosphatase 
 activity as a marker enzyme for the developing vasculature. 
In control embryos, the endogenous alkaline phosphatase activ-
ity labeled the major cerebral and axial vessels as well as the 
subintestinal vessels (SIVs), which develop by angiogenesis 
from the DA at   3 dpf ( Fig. 7, E and F ). In contrast, all MO-DI 
 Figure 7.  Vascular analysis in  Tg(ﬂ i1:egfp) y1 perlecan morphant embryos. (A and B) Epiﬂ uorescence microscopy with 3D deconvolution comparing the 
trunk vasculature of 2-dpf control versus MO-DI embryos. Note the correct formation of DLAV, ISV, DA, and PCV in the control (A). In contrast, the  perlecan 
morphant (B) exhibits abnormal ISVs. Often the ISV sprouts fail to completely migrate along the myoseptae and to anastomose (arrows). (C and D) Merged 
images corresponding to those shown in A and B taken with both ﬂ uorescence deconvolution and DIC microscopy. Note that the ISVs barely reach the 
notochord (NC) and do not properly migrate to the dorsal region, thereby failing to interconnect and properly form the DLAV. (E and F) Lateral and dorsal 
views of alkaline phosphatase – stained control embryos at 3 dpf. Notice the well-developed SIV. (G – I) Three representative MO-DI  perlecan morphants 
showing the complete absence of SIV and reduced alkaline phosphatase staining throughout the trunk vasculature and head region. Notice that J is a higher 
magniﬁ cation of G. The only detectable signal is present along the axial vessels (arrows in G and J). Bars, 500  μ m. 
 o
n
 M
ay 22, 2008 
w
w
w
.jcb.org
D
ow
nloaded from
 
 Published April 21, 2008
JCB • VOLUME 181 • NUMBER 2 • 2008 390 
preparations is shown in  Fig. 8 A . Embryos were injected with 
2.5 ng MO-DI and were randomized into two groups. Half of the 
embryos received phenol red, whereas the other half received 10 ng 
perlecan or domain V/endorepellin. A signifi cant rescue of the 
twisted body phenotype (ranging between 66 and 82%;  n = 29 for 
perlecan and  n = 36 for endorepellin) was achieved by coinjection 
of full-length perlecan or endorepellin. The rescue of the phenotype 
was quite striking, and several zebrafi sh survived up to larval stage 
( Fig. 8, B and C ). Notice that the effects of the morpholinos in the 
rescued morphants are still visible, including slightly bent tails and 
moderate pericardial edema ( Fig. 8, B and C ), indicating that per-
lecan and endorepellin were capable of rescuing the phenotype, at 
least partially. Collectively, these fi ndings complement the immuno-
histochemical data, corroborate the specifi city of our antisense 
strategy, and support a key role for perlecan and endorepellin in 
maintaining cardiovascular and musculoskeletal function. 
 Rescue experiments using human perlecan 
and endorepellin 
 Conclusive determination of any phenotype is generally made 
through targeting of the same gene at several nonoverlapping sites 
using antisense morpholinos or by RNA/protein rescue. Given the 
large size of  perlecan mRNA (predicted mRNA of   12 kb), rescue 
of the morphant phenotype by the overexpression of cRNA encod-
ing full-length zebrafi sh  perlecan would be technically impractical. 
Because of the high degree of homology between human and zebra-
fi sh perlecan, we chose to inject human perlecan or endorepellin. 
The former was immunopurifi ed from human coronary artery endo-
thelial cells using an affi nity column coupled with antiperlecan 
monoclonal antibody ( Whitelock et al., 1999 ), whereas the latter 
was purifi ed from the media conditioned by human embryonic kid-
ney 293 – Epstein-Barr virus nuclear antigen cells stably expressing 
domain V/endorepellin ( Mongiat et al., 2003 ). The purity of the two 
 Figure 8.  Partial rescue of the perlecan morphants by human  perlecan and endorepellin. (A) Coomassie blue – stained 3 – 8% Tris-borate gradient gel of 
human perlecan immunopuriﬁ ed from human coronary artery endothelial cells (left). Note the large and broad band corresponding to  M r of  > 500 kD. 
The right panel shows a Coomassie blue – stained 10% SDS-PAGE of human endorepellin. (B and C) Composite photographs of control, MO-DI, and MO-DI 
coinjected with perlecan or endorepellin at the designated concentrations. The rescue phenotype was calculated based on the degree of body twisting as 
compared with the microinjection of MO-DI alone. Notice the partial rescue of the twisted body phenotype in both cases. Bar, 500  μ m. 
 o
n
 M
ay 22, 2008 
w
w
w
.jcb.org
D
ow
nloaded from
 
 Published April 21, 2008
391PERLECAN IN MUSCLE AND VASCULAR DEVELOPMENT  • ZOELLER ET AL.
mutation in AChE ( ache ;  Behra et al., 2002 ) shows a muscular 
phenotype similar to that of the  perlecan morphants, further 
stressing the role of AChE in generation of the myopathy. 
 The muscular phenotype evoked by blocking  perlecan ex-
pression is similar to that observed in the  sapje mutant, in which 
expression of the zebrafi sh orthologue of the X-linked human 
Duchenne muscular dystrophy, dystrophin, is absent ( Bassett 
et al., 2003 ). The overall loss of myofi laments and muscle archi-
tecture of the  sapje mutant is similar to the ultrastructural appear-
ance of the  perlecan morphant skeletal muscle (see Fig. 6 C of 
 Bassett et al., 2003 ). In the  sapje mutants, however, the sarcomeres 
often collapse as a result of their detachment from the myoseptae, 
a process that leads to enhanced fi ber death. We did not detect 
any clear muscle detachment in the  perlecan morphants, suggest-
ing that other factors are involved in this process. 
 The absence of dystrophin caused by either a mutation in 
exon 4 of the dystrophin gene in  sapje mutants ( Bassett et al., 
2003 ) or by antisense morpholino ( Guyon et al., 2007 ) leads 
to destabilization of the dystrophin-associated protein complex 
analogous to what is observed in mammals. A similar muscular 
phenotype was observed by knockdown of other members of the 
dystrophin-associated protein complex, including dystroglycan 
( Parsons et al., 2002 ) and   -sarcoglycan ( Guyon et al., 2005 ). 
Domain V/endorepellin binds with high affi nity to   -dystroglycan 
( Talts et al., 1999 ), and posttranslational or genetic disruption of 
dystroglycan function also disrupts perlecan binding to dystro-
glycan ( Kanagawa et al., 2005 ). Moreover, perlecan and dystro-
glycan act at the basal side of the  Drosophila follicular epithelium 
to maintain epithelial organization ( Schneider et al., 2006 ). 
Collectively, these data suggest that perlecan is a component of 
a trimolecular complex (laminin – perlecan – dystroglycan) whose 
disruption could be involved in the pathogenesis of glycosylation-
defi cient muscular dystrophy ( Kanagawa et al., 2005 ). Domain V/
endorepellin interacts with nidogen, fi bulin-2, and collagens IV 
and XVIII in basement membranes ( Iozzo, 2005 ;  Knox and 
Whitelock, 2006 ), and interaction of skeletal muscle cells with 
collagen IV is mediated by cell surface – associated perlecan 
( Villar et al., 1999 ). Thus,  perlecan reduction or absence during 
development could lead to abnormal cell matrix interactions. 
 Our fi ndings indicate that perlecan might be directly in-
volved in muscular dystrophy, and, although perlecan mutations 
have been implicated in causing Schwartz-Jampel syndrome 
characterized by myotonia and chondrodysplasia ( Stum et al., 
2006 ;  Rodgers et al., 2007 ), a role for perlecan in the patho-
genesis of muscular dystrophy has never been hypothesized before. 
It will be important to investigate perlecan mutations in humans, 
especially in patients lacking any mutation in established 
human causative genes. 
 A key role for  perlecan in developmental 
angiogenesis and cardiovascular function 
 Anatomically, vascular development in zebrafi sh proceeds as 
in other vertebrates ( Isogai et al., 2001, 2003 ;  Childs et al., 
2002 ;  Lawson and Weinstein, 2002 ). The major axial vessels 
derive from angioblast migration from the lateral plate mesoderm, 
whereas secondary vessels form by angiogenesis shortly af-
ter coalescence of the angioblasts at the midline. Analogous to 
 Discussion 
 In this study, we used a targeted protein depletion approach 
coupled with protein-based rescue experiments to investigate 
the role of perlecan in vertebrate development. Perlecan exhib-
ited novel and unique functions in muscle development and 
 angiogenesis. Moreover, similar phenotypes were observed in 
three distinct genetic backgrounds, including wild type and two 
transgenic fi sh lines. The  perlecan morphants showed a severe 
myopathy characterized by abnormal orientation and reduced 
amounts of actin fi laments and disorganized sarcomeres. In the 
 perlecan morphants, primary ISV sprouts initiated but did not 
completely extend and showed reduced protrusive activity. 
Essentially, vessels were severely constricted or atretic with re-
duced or absent functional circulation as clearly documented by 
live videomicroscopy. Thus, perlecan plays a central role in the 
complex process of angiogenesis by providing guidance for 
 endothelial cell migration and differentiation as well as branch-
ing morphogenesis. 
 Unexpected role for perlecan in 
muscular development 
 In the mouse, perlecan is essential for localizing AChE to the 
neuromuscular junctions ( Peng et al., 1998, 1999 ;  Arikawa-
Hirasawa et al., 2002; Rotundo, 2003 ). As the collagen-tailed 
form of AChE binds directly to perlecan and colocalizes with 
perlecan and AChR when transplanted onto frozen sections 
of muscle, it is likely that perlecan is a major acceptor site for 
AChE at the neuromuscular junctions ( Arikawa-Hirasawa et al., 
2002 ). This concept is further strengthened by the fact that 
perlecan binds to   -dystroglycan and that in the absence of 
  -dystroglycan, neither perlecan nor AChE accumulates at the 
neuromuscular junctions ( Arikawa-Hirasawa et al., 2002 ). More-
over, the cell surface – binding LG domains of muscle agrin and 
perlecan promote AChR clustering in the presence of laminin-2 
( Smirnov et al., 2005 ). The  perlecan morphants displayed a 
marked reduction and mislocalization of AChR, and short clus-
ters of AChE were noted at the myoseptal junctions, often with 
skipping of somites. In the most severe morphant phenotypes, 
AChR clustered in small regions corresponding to intersomitic 
septae, with the somites mostly devoid of AChR. We note that 
in zebrafi sh embryos and larvae, AChE is not clustered as 
in mammalians and is relatively diffuse in the trunk somites 
even though the synaptic currents in larvae appears to be mature 
( Drapeau et al., 2001 ). The lesions were found throughout the 
entire myotomes, demonstrating an essential role for perlecan 
in skeletal muscle development and maintenance. The severity 
and progressive myopathy caused by perlecan defi ciency may 
be partly caused by the fact that zebrafi sh embryonic muscle may 
not possess the regenerative capacity of mammalian muscle (for 
review see  Bassett and Currie, 2003 ). 
 The loss and misalignment of myofi laments could poten-
tially induce abnormal and uncoordinated movement, a plausible 
explanation for twisting of the body and tail and for the circular 
swimming. These fi ndings indicate that perlecan is essential for 
the development and integrity of somitic muscle and suggest a re-
lationship between AChR and perlecan. Notably, a zebrafi sh null 
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 In conclusion, our fi ndings indicate that  perlecan func-
tions as a key regulator of somitic muscle development and angio-
genesis. This study provides new insights into the biology of 
this important macromolecule and its C-terminal angiostatic 
fragment endorepellin and predicts the potential existence of 
human genetic diseases yet to be characterized in which trun-
cated forms of perlecan might directly affect skeletal muscle 
and vascular development without causing embryonic lethality. 
 Materials and methods 
 Zebraﬁ sh embryos,  perlecan morpholino design, and microinjection 
 Wild-type, Tg (ﬂ i1:egfp) y1 ( Lawson and Weinstein, 2002 ), and Tg (vegfr2:
g-rcfp) ( Cross et al., 2003 ) zebraﬁ sh embryos were maintained according to 
common practice at   28 ° C in embryo medium. Before 24 hpf, embryo 
medium was supplemented with phenylthiourea to prevent pigmentation. 
All embryos were housed in the zebraﬁ sh facility of the Kimmel Cancer Center 
(Thomas Jefferson University) and were cared for/used in accordance with 
university Institutional Animal Care and Use Committee guidelines. Between 
1 and 10 ng of morpholino antisense oligonucleotides or morpholino standard 
control oligonucleotide was microinjected into one- to two-cell stage embryos 
as described previously ( Nasevicius and Ekker, 2000 ). Morpholinos (Gene 
Tools, LLC) were designed to either target the 5  untranslated region/ translation 
start of zebraﬁ sh  perlecan (MO-DI) or to target a splice junction within 
 perlecan ’ s domain III (MO-DIII) or domain V (MO-DV).  Perlecan morpholino 
sequences were as follows: DI-MO, AGTCTTTCAACTCGACCTTCATTCC; 
DIII-MO, ACGAGTCAACCTGCACAACACACAC; and DV-MO, CATCAAA-
CCTGCAAAAGAAAAATGT. The morpholino standard control oligonucleotide 
sequence was CCTCTTACCTCAGTTACAATTTATA. Morpholino off-target 
effects were assessed by coknockdown of p53 with a translation-blocking 
p53MO, GCGCCATTGCTTTGCAAGAATTG, as previously described ( Robu 
et al., 2007 ). Gross morphological assessment/phenotypic observations were 
visualized with a stereomicroscope (MZFIII; Leica) or microscope (Axioplan2; 
Carl Zeiss, Inc.), which were equipped with a GFP ﬁ lter set for vascular-
speciﬁ c analysis in the transgenic embryos, and photographed with a camera 
(Axiocam; Carl Zeiss, Inc.) and AxioVision software version 3.0.6.1 (Carl 
Zeiss, Inc.). All embryos were mounted in 3 – 4% methylcellulose on glass 
slides and anesthetized with Tricaine when necessary. 
 Live imaging and digital microscopy 
 DIC and 3D deconvolved GFP images were collected on a ﬂ uorescent micro-
scope (DM5500 B; Leica) equipped with a camera (DFC340 FX; Leica) and 
LAS AF version 1.6.1 (Leica). Live videos with DIC microscopy were captured 
on the same platform. All video ﬁ les were exported as AVI ﬁ les, which were 
edited in Vegas Movie Studio version 6.0 (Sony) and rendered in QuickTime 
Pro version 7.0 (Microsoft). All embryos were mounted in 3 – 4% methylcellulose 
on glass slides and anesthetized with Tricaine when necessary. 
 Zebraﬁ sh whole mount immunohistochemistry 
 Zebraﬁ sh embryos were ﬁ xed in 4% PFA (Thermo Fisher Scientiﬁ c) in PBS 
overnight at 4 ° C. Postﬁ xation embryos were washed three times over 10 min 
in 1 × PBST (PBS + 0.1% Tween 20), and chorions were removed. Embryos 
were permeabilized by immersion ﬁ rst in distilled H 2 O for 5 min followed by 
immersion in ice-cold acetone at   20 ° C for 7 min and immersion in distilled 
H 2 O for 5 min. Embryos were rehydrated in decreasing methanol/PBST se-
ries (5 min each in 75, 50, and 25%) followed by washing twice over 3 min 
in PBST. Blocking was performed for a minimum of 4 h by immersing the em-
bryos in a solution of 0.1 – 0.2% BSA (Sigma-Aldrich) at room temperature. 
Embryos were incubated with the primary antibody, rabbit anti – mouse 
perlecan, as previously described ( Handler et al., 1997 ) at a 1:250 dilution 
in blocking solution overnight at 4 ° C. Embryos were washed in blocking 
solution four times over at least 25 – 30 min. Embryos were incubated with 
the secondary antibody, donkey anti – rabbit HRP (GE Healthcare), at a 
1:1,000 dilution in blocking solution for   4 h at room temperature. Embryos 
were washed in blocking solution four times over at least 25 – 30 min. Antibody 
staining was visualized by DAB color development according to the manu-
facturer ’ s instructions (Dako). Staining reactions were terminated by substrate 
removal and thorough washing in 1 × PBST. Antibody staining was per-
formed on groups of two to ﬁ ve embryos. Embryos incubated with second-
ary antibody alone served as controls. All embryos were photographed 
in PBST on an MZFIII stereomicroscope or Axioplan2 microscope with an 
Axiocam camera and AxioVision software version 3.0.6.1. 
perlecan knockdown, suppression of  Vegfa by antisense morpho-
lino ( Nasevicius et al., 2000 ) or VEGF receptor blockade by the 
small molecule SU5416 ( Cross et al., 2003 ) inhibits ISV for-
mation and causes pericardial edema. These data suggest that 
the pathology caused by the knockdown of  perlecan or VEGFA 
is caused by an aberrant vascular system rather than by non-
specifi c effects. 
 Using two transgenic lines of zebrafi sh expressing  gfp 
driven by the promoter of  fl i1 , an ETS domain transcription fac-
tor specifi c for cells of the hemangioblastic lineage, or  vegfr2/
fl k1 , the major receptor for VEGF, we showed that perlecan was 
not required for endothelial cell differentiation and vasculo-
genesis. However,  perlecan knockdown caused a marked reduction 
in circulating blood cells in the most severe phenotypes, sug-
gesting a potential role for  perlecan in the establishment of an-
gioblast differentiation and lineage.  Perlecan morphants showed 
a marked impairment in the ability of  vegfr2/fl i1 -expressing 
endothelial cells to migrate along the intersomitic septae and 
form arterio-venous channels. The live videomicroscopy analy-
sis clearly showed a wide spectrum of vascular changes ranging 
from a reduced to a complete lack of circulatory cells in the ISV, 
DLAV, and SIV. Disruption of ISV and SIV by knockdown of 
 perlecan is particularly interesting because these vessels de-
velop by angiogenic sprouting, a process that closely resembles 
tumor angiogenesis. Notably, antisense targeting of perlecan 
blocks tumor growth and angiogenesis in vivo ( Aviezer et al., 
1997 ;  Sharma et al., 1998 ). 
 We do not know whether the abnormal endothelial cell mi-
gration and pathfi nding is caused by a structural role, abnormal 
signaling of molecules involved in angiogenesis, or a combina-
tion of both. Ultrastructural analysis of vascular, epithelial, and 
notochord basement membranes revealed no signifi cant abnor-
malities in the  perlecan morphants, which is in keeping with the 
fi ndings of the perlecan-null mouse ( Arikawa-Hirasawa et al., 
1999 ;  Costell et al., 1999 ). We favor the possibility that part of 
the vascular phenotype in the  perlecan morphants is caused by 
abnormal signaling events mediated by hedgehog ( hh ) and Vegf 
proteins and their receptors ( Covassin et al., 2006 ). 
 Perlecan regulates signaling via protein – protein and protein –
 carbohydrate interactions ( Iozzo, 1998 ), and recent evidence 
indicates that perlecan regulates  shh signaling during development 
( Park et al., 2003 ) and cancer ( Datta et al., 2006a , b ;  Lindner 
et al., 2007 ). In zebrafi sh embryos, Hh is secreted by the midline 
structures (fl oor plate, notochord, and hypochord) and is at the 
top of the signaling cascade controlling vasculogenesis, which 
also includes  vegf and  notch ( Lawson et al., 2001, 2002 ). More-
over, Hh is not only required for adult blood stem cell formation 
and for the expression of artery-specifi c genes by aortic endo-
thelial cells but is also required for angiogenic sprouting of primary 
ISV ( Gering and Patient, 2005 ). Interestingly, Hh is essential 
for endothelial chord and tube formation in avian and murine 
embryos ( Vokes et al., 2004 ), suggesting that its role in vasculo-
genesis is conserved in vertebrate embryos. Thus, a plausible 
scenario is that during somitogenesis and vasculogenesis, Hh 
activity is perturbed by the lack of perlecan, which might also 
affect the  vegf – vegfr2 axis as well as other potential players 
such as the  fgf – fgfr signaling pathway. 
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